Review



automatic injector as 1555  (JASCO Inc)


Bioz Verified Symbol JASCO Inc is a verified supplier
Bioz Manufacturer Symbol JASCO Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    JASCO Inc automatic injector as 1555
    Automatic Injector As 1555, supplied by JASCO Inc, used in various techniques. Bioz Stars score: 97/100, based on 24474 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/automatic injector as 1555/product/JASCO Inc
    Average 97 stars, based on 24474 article reviews
    automatic injector as 1555 - by Bioz Stars, 2026-02
    97/100 stars

    Images



    Similar Products

    99
    ATCC 1555 rrid cvcl 0037
    1555 Rrid Cvcl 0037, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/1555 rrid cvcl 0037/product/ATCC
    Average 99 stars, based on 1 article reviews
    1555 rrid cvcl 0037 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    97
    JASCO Inc automatic injector as 1555
    Automatic Injector As 1555, supplied by JASCO Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/automatic injector as 1555/product/JASCO Inc
    Average 97 stars, based on 1 article reviews
    automatic injector as 1555 - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    a431  (ATCC)
    99
    ATCC a431
    Schematic showing generation of isogenic <t>A431-HA</t> tagged cells engineered to express either KRAS WT or mutant KRAS G12V (A) Generation of retrovirus by transfecting HEK293T cells with vector expressing either KRAS-WT-HA or KRAS-G12V-HA and retroviral packaging vector. Retroviral particles are collected and filtered. (B) Generation of lentivirus by transfection HEK293T cells with vector expressing either KRAS-WT-Luc or KRAS-G12V-Luc and lentiviral packaging vectors. Lentiviral particles are collected and filtered. (C) Remove endogenous KRAS from A431 cells using CRISPR/Cas9 and identify clones by single cell cloning and PCR. (D) Transduce A431 KRAS knockout cells with retrovirus/lentivirus and select for successfully transduced cells using puromycin resulting in A431 cells expressing KRAS with HA tag or luciferase reporter.
    A431, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a431/product/ATCC
    Average 99 stars, based on 1 article reviews
    a431 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC epidermoid carcinoma cell line
    Schematic showing generation of isogenic <t>A431-HA</t> tagged cells engineered to express either KRAS WT or mutant KRAS G12V (A) Generation of retrovirus by transfecting HEK293T cells with vector expressing either KRAS-WT-HA or KRAS-G12V-HA and retroviral packaging vector. Retroviral particles are collected and filtered. (B) Generation of lentivirus by transfection HEK293T cells with vector expressing either KRAS-WT-Luc or KRAS-G12V-Luc and lentiviral packaging vectors. Lentiviral particles are collected and filtered. (C) Remove endogenous KRAS from A431 cells using CRISPR/Cas9 and identify clones by single cell cloning and PCR. (D) Transduce A431 KRAS knockout cells with retrovirus/lentivirus and select for successfully transduced cells using puromycin resulting in A431 cells expressing KRAS with HA tag or luciferase reporter.
    Epidermoid Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epidermoid carcinoma cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    epidermoid carcinoma cell line - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    a 431  (ATCC)
    99
    ATCC a 431
    Schematic showing generation of isogenic <t>A431-HA</t> tagged cells engineered to express either KRAS WT or mutant KRAS G12V (A) Generation of retrovirus by transfecting HEK293T cells with vector expressing either KRAS-WT-HA or KRAS-G12V-HA and retroviral packaging vector. Retroviral particles are collected and filtered. (B) Generation of lentivirus by transfection HEK293T cells with vector expressing either KRAS-WT-Luc or KRAS-G12V-Luc and lentiviral packaging vectors. Lentiviral particles are collected and filtered. (C) Remove endogenous KRAS from A431 cells using CRISPR/Cas9 and identify clones by single cell cloning and PCR. (D) Transduce A431 KRAS knockout cells with retrovirus/lentivirus and select for successfully transduced cells using puromycin resulting in A431 cells expressing KRAS with HA tag or luciferase reporter.
    A 431, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a 431/product/ATCC
    Average 99 stars, based on 1 article reviews
    a 431 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC a431 cells
    Establishment of HAS2 KO cells and confirmation of HA synthesis. A , comparison of HAS2 expression levels among different cell lines: HeLa (cervical adenocarcinoma cell line), <t>A431</t> (epidermoid carcinoma cell line), PANC-1 (pancreatic ductal adenocarcinoma cell line), MIA PaCa-2 (pancreatic carcinoma cell line), and HepG2 (hepatocellular carcinoma cell line). The HAS2 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. B , comparison of HAS1 , HAS2 , and HAS3 expression levels in HeLa cells. The HAS1 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. C , Sanger sequencing was used to analyze exon 2 of the target sequence in HeLa WT and HAS2 KO cells with the canonical SpCas9 PAM sequence (TGG) highlighted in bold. D , WT and HAS2 KO cells were cultured in serum-free medium, and the conditioned medium was collected after 24 h to measure HA concentration. Statistical significance was determined from three independent experiments using an unpaired Student’s t test, with p values indicated as ∗∗∗ p < 0.001.
    A431 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a431 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    a431 cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC a431 human epidermoid carcinoma cell line
    Establishment of HAS2 KO cells and confirmation of HA synthesis. A , comparison of HAS2 expression levels among different cell lines: HeLa (cervical adenocarcinoma cell line), <t>A431</t> (epidermoid carcinoma cell line), PANC-1 (pancreatic ductal adenocarcinoma cell line), MIA PaCa-2 (pancreatic carcinoma cell line), and HepG2 (hepatocellular carcinoma cell line). The HAS2 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. B , comparison of HAS1 , HAS2 , and HAS3 expression levels in HeLa cells. The HAS1 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. C , Sanger sequencing was used to analyze exon 2 of the target sequence in HeLa WT and HAS2 KO cells with the canonical SpCas9 PAM sequence (TGG) highlighted in bold. D , WT and HAS2 KO cells were cultured in serum-free medium, and the conditioned medium was collected after 24 h to measure HA concentration. Statistical significance was determined from three independent experiments using an unpaired Student’s t test, with p values indicated as ∗∗∗ p < 0.001.
    A431 Human Epidermoid Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a431 human epidermoid carcinoma cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    a431 human epidermoid carcinoma cell line - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC a 431 cells
    Establishment of HAS2 KO cells and confirmation of HA synthesis. A , comparison of HAS2 expression levels among different cell lines: HeLa (cervical adenocarcinoma cell line), <t>A431</t> (epidermoid carcinoma cell line), PANC-1 (pancreatic ductal adenocarcinoma cell line), MIA PaCa-2 (pancreatic carcinoma cell line), and HepG2 (hepatocellular carcinoma cell line). The HAS2 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. B , comparison of HAS1 , HAS2 , and HAS3 expression levels in HeLa cells. The HAS1 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. C , Sanger sequencing was used to analyze exon 2 of the target sequence in HeLa WT and HAS2 KO cells with the canonical SpCas9 PAM sequence (TGG) highlighted in bold. D , WT and HAS2 KO cells were cultured in serum-free medium, and the conditioned medium was collected after 24 h to measure HA concentration. Statistical significance was determined from three independent experiments using an unpaired Student’s t test, with p values indicated as ∗∗∗ p < 0.001.
    A 431 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/a 431 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    a 431 cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC cutaneous squamous cell carcinoma
    Establishment of HAS2 KO cells and confirmation of HA synthesis. A , comparison of HAS2 expression levels among different cell lines: HeLa (cervical adenocarcinoma cell line), <t>A431</t> (epidermoid carcinoma cell line), PANC-1 (pancreatic ductal adenocarcinoma cell line), MIA PaCa-2 (pancreatic carcinoma cell line), and HepG2 (hepatocellular carcinoma cell line). The HAS2 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. B , comparison of HAS1 , HAS2 , and HAS3 expression levels in HeLa cells. The HAS1 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. C , Sanger sequencing was used to analyze exon 2 of the target sequence in HeLa WT and HAS2 KO cells with the canonical SpCas9 PAM sequence (TGG) highlighted in bold. D , WT and HAS2 KO cells were cultured in serum-free medium, and the conditioned medium was collected after 24 h to measure HA concentration. Statistical significance was determined from three independent experiments using an unpaired Student’s t test, with p values indicated as ∗∗∗ p < 0.001.
    Cutaneous Squamous Cell Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cutaneous squamous cell carcinoma/product/ATCC
    Average 99 stars, based on 1 article reviews
    cutaneous squamous cell carcinoma - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    Image Search Results


    Schematic showing generation of isogenic A431-HA tagged cells engineered to express either KRAS WT or mutant KRAS G12V (A) Generation of retrovirus by transfecting HEK293T cells with vector expressing either KRAS-WT-HA or KRAS-G12V-HA and retroviral packaging vector. Retroviral particles are collected and filtered. (B) Generation of lentivirus by transfection HEK293T cells with vector expressing either KRAS-WT-Luc or KRAS-G12V-Luc and lentiviral packaging vectors. Lentiviral particles are collected and filtered. (C) Remove endogenous KRAS from A431 cells using CRISPR/Cas9 and identify clones by single cell cloning and PCR. (D) Transduce A431 KRAS knockout cells with retrovirus/lentivirus and select for successfully transduced cells using puromycin resulting in A431 cells expressing KRAS with HA tag or luciferase reporter.

    Journal: STAR Protocols

    Article Title: Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches

    doi: 10.1016/j.xpro.2025.104323

    Figure Lengend Snippet: Schematic showing generation of isogenic A431-HA tagged cells engineered to express either KRAS WT or mutant KRAS G12V (A) Generation of retrovirus by transfecting HEK293T cells with vector expressing either KRAS-WT-HA or KRAS-G12V-HA and retroviral packaging vector. Retroviral particles are collected and filtered. (B) Generation of lentivirus by transfection HEK293T cells with vector expressing either KRAS-WT-Luc or KRAS-G12V-Luc and lentiviral packaging vectors. Lentiviral particles are collected and filtered. (C) Remove endogenous KRAS from A431 cells using CRISPR/Cas9 and identify clones by single cell cloning and PCR. (D) Transduce A431 KRAS knockout cells with retrovirus/lentivirus and select for successfully transduced cells using puromycin resulting in A431 cells expressing KRAS with HA tag or luciferase reporter.

    Article Snippet: A431 , ATCC , Cat #CRL-1555; RRID: CVCL_0037.

    Techniques: Mutagenesis, Plasmid Preparation, Expressing, Retroviral, Transfection, CRISPR, Clone Assay, Cloning, Knock-Out, Luciferase

    Schematic showing experimental workflow for in vitro evaluation of KRAS G12V selective siRNA (A) A431-KRAS(G12V/WT)-HA cells are transfected with siRNA using Lipofectamine RNAiMAX. After 48 hours, cells are collected and RNA is isolated and used for RT-qPCR for relevant mRNA targets. After 72 hours, cells are collected and protein is isolated and used for immunoblotting for relevant targets. (B) A431-KRAS(WT/G12V)-Luc cells are transfected with a serial dilution of siRNA using Lipofectamine RNAiMAX and plated into 96-well opaque plates. After 3 days, firefly and renilla luciferase readouts are completed.

    Journal: STAR Protocols

    Article Title: Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches

    doi: 10.1016/j.xpro.2025.104323

    Figure Lengend Snippet: Schematic showing experimental workflow for in vitro evaluation of KRAS G12V selective siRNA (A) A431-KRAS(G12V/WT)-HA cells are transfected with siRNA using Lipofectamine RNAiMAX. After 48 hours, cells are collected and RNA is isolated and used for RT-qPCR for relevant mRNA targets. After 72 hours, cells are collected and protein is isolated and used for immunoblotting for relevant targets. (B) A431-KRAS(WT/G12V)-Luc cells are transfected with a serial dilution of siRNA using Lipofectamine RNAiMAX and plated into 96-well opaque plates. After 3 days, firefly and renilla luciferase readouts are completed.

    Article Snippet: A431 , ATCC , Cat #CRL-1555; RRID: CVCL_0037.

    Techniques: In Vitro, Transfection, Isolation, Quantitative RT-PCR, Western Blot, Serial Dilution, Luciferase

    Schematic showing experimental workflow for in vivo evaluations of KRAS G12V selective siRNA in tumor and mouse somatic tissues Mice are subcutaneously injected with A431-KRAS(G12V)-HA cancer cells and mice form tumors which are monitored by caliper measurement. After 1–2 weeks, mice are subcutaneously injected (away from the tumor) with the KRAS G12V siRNA. Tumor and mouse somatic tissues (kidney, bladder and skin) are collected at multiple timepoints from 24–96 hours after injection. Tissues are cut into smaller sections and processed with TRIzol for RNA isolation. RNA is used for RT-qPCR for relevant mRNA targets.

    Journal: STAR Protocols

    Article Title: Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches

    doi: 10.1016/j.xpro.2025.104323

    Figure Lengend Snippet: Schematic showing experimental workflow for in vivo evaluations of KRAS G12V selective siRNA in tumor and mouse somatic tissues Mice are subcutaneously injected with A431-KRAS(G12V)-HA cancer cells and mice form tumors which are monitored by caliper measurement. After 1–2 weeks, mice are subcutaneously injected (away from the tumor) with the KRAS G12V siRNA. Tumor and mouse somatic tissues (kidney, bladder and skin) are collected at multiple timepoints from 24–96 hours after injection. Tissues are cut into smaller sections and processed with TRIzol for RNA isolation. RNA is used for RT-qPCR for relevant mRNA targets.

    Article Snippet: A431 , ATCC , Cat #CRL-1555; RRID: CVCL_0037.

    Techniques: In Vivo, Injection, Isolation, Quantitative RT-PCR

    Validation of mutant selectivity of KRAS G12V siRNA in vitro (A) UV melting curves and sequences of 23mer duplexes between the fully modified KRAS guide RNA and the targeted G12V mutant, WT, and G12D mutant RNA. (B) Western blot analysis in A431 cells stably expressing KRAS WT or G12V transiently transfected with siRNAs. Cells were analyzed at 48 hours and 72 hours. Blots were done separately, and densitometry quantification below is based on vinculin control for each individual blot. (C) RT-qPCR analysis in A431 cells transiently transfected with siRNAs at 20 nM. Cells were analyzed at 48 hours. Data shown as mean +/- SEM, experiments performed in duplicate. (D) Luciferase dose-response curve in A431-KRAS-WT or A431-KRAS-G12V cells stably expressing a luciferase reporter. Cells were analyzed at 72 hours. Data shown as mean +/- SEM, experiments performed in triplicate. (E) Volcano plots from RNA-sequencing in SKCO1 cells transiently transfected with siRNAs at 20 nM. Cells were analyzed at 24 hours. This figure includes data published in Stanland et al and has received permission to be shown in this figure.

    Journal: STAR Protocols

    Article Title: Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches

    doi: 10.1016/j.xpro.2025.104323

    Figure Lengend Snippet: Validation of mutant selectivity of KRAS G12V siRNA in vitro (A) UV melting curves and sequences of 23mer duplexes between the fully modified KRAS guide RNA and the targeted G12V mutant, WT, and G12D mutant RNA. (B) Western blot analysis in A431 cells stably expressing KRAS WT or G12V transiently transfected with siRNAs. Cells were analyzed at 48 hours and 72 hours. Blots were done separately, and densitometry quantification below is based on vinculin control for each individual blot. (C) RT-qPCR analysis in A431 cells transiently transfected with siRNAs at 20 nM. Cells were analyzed at 48 hours. Data shown as mean +/- SEM, experiments performed in duplicate. (D) Luciferase dose-response curve in A431-KRAS-WT or A431-KRAS-G12V cells stably expressing a luciferase reporter. Cells were analyzed at 72 hours. Data shown as mean +/- SEM, experiments performed in triplicate. (E) Volcano plots from RNA-sequencing in SKCO1 cells transiently transfected with siRNAs at 20 nM. Cells were analyzed at 24 hours. This figure includes data published in Stanland et al and has received permission to be shown in this figure.

    Article Snippet: A431 , ATCC , Cat #CRL-1555; RRID: CVCL_0037.

    Techniques: Biomarker Discovery, Mutagenesis, In Vitro, Modification, Western Blot, Stable Transfection, Expressing, Transfection, Control, Quantitative RT-PCR, Luciferase, RNA Sequencing

    Establishment of HAS2 KO cells and confirmation of HA synthesis. A , comparison of HAS2 expression levels among different cell lines: HeLa (cervical adenocarcinoma cell line), A431 (epidermoid carcinoma cell line), PANC-1 (pancreatic ductal adenocarcinoma cell line), MIA PaCa-2 (pancreatic carcinoma cell line), and HepG2 (hepatocellular carcinoma cell line). The HAS2 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. B , comparison of HAS1 , HAS2 , and HAS3 expression levels in HeLa cells. The HAS1 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. C , Sanger sequencing was used to analyze exon 2 of the target sequence in HeLa WT and HAS2 KO cells with the canonical SpCas9 PAM sequence (TGG) highlighted in bold. D , WT and HAS2 KO cells were cultured in serum-free medium, and the conditioned medium was collected after 24 h to measure HA concentration. Statistical significance was determined from three independent experiments using an unpaired Student’s t test, with p values indicated as ∗∗∗ p < 0.001.

    Journal: The Journal of Biological Chemistry

    Article Title: Hyaluronic acid regulates cellular UDP-GlcNAc levels through CD44 to affect glycosylation and cell biological functions

    doi: 10.1016/j.jbc.2025.111111

    Figure Lengend Snippet: Establishment of HAS2 KO cells and confirmation of HA synthesis. A , comparison of HAS2 expression levels among different cell lines: HeLa (cervical adenocarcinoma cell line), A431 (epidermoid carcinoma cell line), PANC-1 (pancreatic ductal adenocarcinoma cell line), MIA PaCa-2 (pancreatic carcinoma cell line), and HepG2 (hepatocellular carcinoma cell line). The HAS2 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. B , comparison of HAS1 , HAS2 , and HAS3 expression levels in HeLa cells. The HAS1 mRNA level in HeLa was normalized to 1.0. All values are presented as mean ± SD from three independent experiments, based on one-way ANOVA with Tukey’s post hoc analysis. ∗∗∗ p < 0.001. C , Sanger sequencing was used to analyze exon 2 of the target sequence in HeLa WT and HAS2 KO cells with the canonical SpCas9 PAM sequence (TGG) highlighted in bold. D , WT and HAS2 KO cells were cultured in serum-free medium, and the conditioned medium was collected after 24 h to measure HA concentration. Statistical significance was determined from three independent experiments using an unpaired Student’s t test, with p values indicated as ∗∗∗ p < 0.001.

    Article Snippet: A431 cells were obtained from ATCC.

    Techniques: Comparison, Expressing, Sequencing, Cell Culture, Concentration Assay